comparemela.com

Latest Breaking News On - Prnewswire fusion pharmaceuticals inc - Page 6 : comparemela.com

Fusion Pharmaceuticals to Present at the Jefferies Healthcare Conference

HAMILTON, ON and BOSTON, May 31, 2023 /PRNewswire/ Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision. | May 31, 2023

United statesAmanda crayJohn valliantPrnewswire fusion pharmaceuticals incNiowave incInvestor relations corporate communicationsFusion pharmaceuticalsJefferies healthcare conferenceChief executive officer john valliantResponse inhibitorsInvestor relationsFusn phar stock exchangePress releaseS fusn ca36118a1003

Fusion Pharmaceuticals to Present at the Jefferies Healthcare Conference

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as.

United statesJohn valliantAmanda crayInvestor relations corporate communicationsNiowave incPrnewswire fusion pharmaceuticals incFusion pharmaceuticalsJefferies healthcare conferenceChief executive officer john valliantResponse inhibitorsInvestor relations

Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates

FPI-2265 (Ac-PSMA I&T) program enrolling patients and on track for Q1 2024 update Preliminary Phase 1 data for FPI-1434 expected to be reported at the Society.

United statesAmanda crayDmitri bobilevJohn valliantFusion pharmaceuticals incPrnewswire fusion pharmaceuticals incInvestor relations corporate communicationsDrug administrationFusion pharmaceuticalsNiowave incExchange commissionSociety of nuclear medicineNuclear medicineMolecular imagingFederated hermes kaufmann fundsExecutive officer john valliant

Fusion Pharmaceuticals to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as.

United statesAmanda crayJohn valliantPrnewswire fusion pharmaceuticals incFusion pharmaceuticalsNiowave incInvestor relations corporate communicationsChief executive officer john valliantResponse inhibitorsInvestor relations

Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha Therapy

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as.

United statesAmanda crayJohn valliantFusion pharmaceuticals incInvestor relations corporate communicationsDrug administrationNiowave incFusion pharmaceuticalsPrnewswire fusion pharmaceuticals incBispecific targeted alpha therapyPrecisely deliver radiationResponse inhibitorsPrivate securities litigation reform actInvestor relations

vimarsana © 2020. All Rights Reserved.